Video
Understanding Glycogen Storage Disease Type 1b and its impacts. Only Muscle pain in glycogen storage disease seeking Elegant improve the Muscpe and pai of information Elegant Low-carb on a budget Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed. Orphanet doesn't provide personalised answers. To get in touch with the Orphanet team, please contact.Muscle pain in glycogen storage disease -
The forms of the mutations may vary between ethnic groups. For example, the R50X Arg50Stop mutation previously referred to as R49X is most common in North America and western Europe, and the Y84X mutation is most common among central Europeans. The exact method of protein disruption has been elucidated in certain mutations.
For example, RW is known to disrupt to pyridoxal phosphate binding site. The myophosphorylase structure consists of amino acids.
Its molecular weight of the unprocessed precursor is 97 kDa. The three-dimensional structure has been determined for this protein. The interactions of several amino acids in myophosphorylase's structure are known. Ser is modified by phosphorylase kinase during activation of the enzyme.
Lys is involved in binding the pyridoxal phosphate, which is the active form of vitamin B 6 , a cofactor required by myophosphorylase. By similarity, other sites have been estimated: Tyr binds AMP, Cys and Cys are involved in subunit association, and Tyr may be involved in allosteric control.
Myophosphorylase is the form of the glycogen phosphorylase found in muscle that catalyses the following reaction: [32] [33] [34]. Failure of this enzyme ultimately impairs the operation of ATPases. This is due to the lack of normal pH fall during exercise, which impairs the creatine kinase equilibrium and exaggerates the rise of ADP.
Myophosphorylase is involved in the breakdown of glycogen to glucosephosphate for use in muscle. The enzyme removes 1,4 glycosyl residues from outer branches of glycogen and adds inorganic phosphate to form glucosephosphate.
Ordinarily, the removal of 1,4 glycosyl residues by myophosphorylase leads to the formation of glucosephosphate during glycogen breakdown and the polar, phosphorylated glucose cannot leave the cell membrane and so is marked for intracellular catabolism.
In McArdle's Disease, deficiency of myophosphorylase leads to accumulation of intramuscular glycogen and a lack of glucosephosphate for cellular fuel. Myophosphorylase comes in two forms: form 'a' is phosphorylated by phosphorylase kinase , form 'b' is not phosphorylated.
Form 'a' is de-phosphorylated into form 'b' by the enzyme phosphoprotein phosphatase , which is activated by elevated insulin. Both forms have two conformational states: active R or relaxed and inactive T or tense.
When either form 'a' or 'b' are in the active state, then the enzyme converts glycogen into glucosephosphate. Myophosphorylase-a is active, unless allosterically inactivated by elevated glucose within the cell. In this way, myophosphorylase-a is the more active of the two forms as it will continue to convert glycogen into glucosephosphate even with high levels of glycogenphosphate and ATP.
See Glycogen phosphorylase§Regulation. There are some laboratory tests that may aid in diagnosis of GSD-V. A muscle biopsy will note the absence of myophosphorylase in muscle fibers.
In some cases, abnormal accumulation of glycogen stained by periodic acid-Schiff can be seen with microscopy. Genetic sequencing of the PYGM gene which codes for the muscle isoform of glycogen phosphorylase [35] [36] may be done to determine the presence of gene mutations , determining if McArdle's is present.
This type of testing is considerably less invasive than a muscle biopsy. The physician can also perform an ischemic forearm exercise test as described above. Some findings suggest a nonischemic test could be performed with similar results.
Findings consistent with McArdle's disease would include a failure of lactate to rise in venous blood and exaggerated ammonia levels. These findings would indicate a severe muscle glycolytic block. Serum lactate may fail to rise in part because of increased uptake via the monocarboxylate transporter MCT1 , which is upregulated in skeletal muscle in McArdle disease.
Lactate may be used as a fuel source once converted to pyruvate. Ammonia levels may rise given ammonia is a by-product of AMP deaminase which follows after the production of AMP by adenylate kinase , an alternative pathway for ATP production.
In this pathway, adenylate kinase combines two ADP molecules to make ATP and AMP; AMP is then deaminated , producing inosine monophosphate IMP and ammonia NH 3 as part of purine nucleotide cycle. This can help distinguish McArdle's syndrome from carnitine palmitoyltransferase II deficiency CPT-II , a lipid-based metabolic disorder which prevents fatty acids from being transported into mitochondria for use as an energy source.
Also, serum electrolytes and endocrine studies such as thyroid function, parathyroid function and growth hormone levels will also be completed. Urine studies are required only if rhabdomyolysis is suspected. Urine volume, urine sediment and myoglobin levels would be ascertained.
If rhabdomyolysis is suspected, serum myoglobin, creatine kinase, lactate dehydrogenase, electrolytes and renal function will be checked. Physicians may also conduct an exercise stress test to test for an inappropriate rapid heart rate sinus tachycardia in response to exercise. Due to the rare nature of the disease, the inappropriate rapid heart rate in response to exercise may be misdiagnosed as inappropriate sinus tachycardia which is a diagnosis of exclusion.
The 12 Minute Walk Test 12MWT can be used to determine " second wind ," which requires a treadmill no incline , heart rate monitor, stop watch, pain scale, and that the patient has rested for 30 minutes prior to the test to ensure that "second wind" has stopped that is, that increased ATP production primarily from free fatty acids has returned to resting levels.
Electromyography EMG may show normal or myopathic results short duration, polyphasic, small amplitude MUAPs. The myopathic results were a decrease in CMAP amplitude, which was evident immediately after exercise and, after a plateau phase of a few minutes, reached its maximum after 30 minutes.
Dynamic symptoms of exercise intolerance e. muscle fatigue and cramping with or without fixed proximal muscle weakness:. Allelic to McArdle disease GSD-V is a recently discovered disease that has a pathogenic autosomal dominant mutation on the PYGM gene.
It impairs the ability of myophosphorylase to become phosphorylated, that is to be converted from myophosphorylase-b into myophosphorylase-a. Myophosphorylase-b can be activated to break down glycogen glycogenolysis by high levels of AMP, and as the amp-dependent activity was preserved, this disease does not have exercise intolerance which is a prominent distinguishing feature from McArdle disease.
The only symptom was adult-onset fixed muscle weakness. Muscle biopsy also showed accumulation of the intermediate filament desmin in the myofibres. Supervised exercise programs have been shown in small studies to improve exercise capacity by several measures: lowering heart rate, lowering serum creatine kinase CK , increasing the exercise intensity threshold before symptoms of muscle fatigue and cramping are experienced, and the skeletal muscles becoming aerobically conditioned.
Oral sucrose treatment for example a sports drink with 75 grams of sucrose in ml. taken 30 minutes prior to exercise has been shown to help improve exercise tolerance, including a lower heart rate and lower perceived level of exertion compared with placebo.
However, the ingestion of a high-carbohydrate meal or drink is problematic as a frequent form of treatment since it will increase the release of insulin , which inhibits the release of fatty acids [46] and subsequently will delay the ability to get into second wind.
sugary drinks , in order to avoid premature muscle fatigue and cramping, is also problematic in that it can lead to obesity as insulin will also stimulate triglyceride synthesis develop body fat , [46] and obesity-related ill health e.
type II diabetes and heart disease. A low dosage treatment with creatine showed a significant improvement of muscle problems compared to placebo in a small clinical study, while other studies have shown minimal subjective benefit.
A ketogenic diet has demonstrated beneficial for McArdle disease GSD-V as ketones readily convert to acetyl CoA for oxidative phosphorylation, whereas free fatty acids take a few minutes to convert into acetyl CoA.
The deficiency was the first metabolic myopathy to be recognized, when the physician Brian McArdle described the first case in a year-old man who always experienced pain and weakness after exercise.
McArdle noticed this patient's cramps were electrically silent and his venous lactate levels failed to increase upon ischemic exercise.
The weakness generally affects the muscles closest to the center of the body proximal muscles. The hemolytic form of GSDVII is characterized by hemolytic anemia, in which red blood cells are broken down undergo hemolysis prematurely, causing a shortage of red blood cells anemia.
People with the hemolytic form of GSDVII do not experience any signs or symptoms of muscle pain or weakness related to the disorder. GSDVII is thought to be a rare condition; more than cases have been described in the scientific literature.
Mutations in the PFKM gene cause GSDVII. This gene provides instructions for making one piece the PFKM subunit of an enzyme called phosphofructokinase, which plays a role in the breakdown of glycogen. The phosphofructokinase enzyme is made up of four subunits and is found in a variety of tissues.
Different combinations of subunits are found in different tissues. In muscles used for movement skeletal muscles , the phosphofructokinase enzyme is composed solely of PFKM subunits. In skeletal muscle, the cells' main source of energy is stored as glycogen.
Glycogen can be broken down rapidly into the simple sugar glucose when energy is needed, for instance to maintain normal blood glucose levels between meals or for energy during exercise. Phosphofructokinase is involved in the sequence of events that breaks down glycogen to provide energy to muscle cells.
PFKM gene mutations result in the production of PFKM subunits that have little or no function. As a result, no functional phosphofructokinase is formed in skeletal muscles, and glycogen cannot be completely broken down.
Partially broken down glycogen then builds up in muscle cells. Muscles that do not have access to glycogen as an energy source become weakened and cramped following moderate strain, such as exercise, and in some cases, begin to break down.
In other tissues, other subunits that make up the phosphofructokinase enzyme likely compensate for the lack of PFKM subunits, and the enzyme is able to retain some function. This compensation may help explain why other tissues are not affected by PFKM gene mutations.
It is unclear why some individuals with GSDVII are affected with more severe forms of the disorder than others. This condition is inherited in an autosomal recessive pattern , which means both copies of the gene in each cell have mutations.
The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition. The information on this site should not be used as a substitute for professional medical care or advice.
Contact a health care provider if you have questions about your health. Glycogen storage disease type VII.
Description Glycogen storage disease type VII GSDVII is an inherited disorder caused by an inability to break down a complex sugar called glycogen in muscle cells. Frequency GSDVII is thought to be a rare condition; more than cases have been described in the scientific literature.
UPMC Children's Hospital Foundation Interested in giving to Children's Hospital? Support the hospital by making a donation online , joining our Heroes in Healing monthly donor program , or visiting our site to learn about the other ways you can give back.
Children's Hospital is part of the UPMC family. UPMC Website UPMC's Story. Our Sites. Liver Disease States. Liver Transplant. Glycogen Storage Diseases GSD in Children What Is Glycogen Storage Disease? Types of Glycogen Storage Disease The main types of glycogen storage diseases in children are categorized by number and name.
Glycogen Storage Disease Symptoms Glycogen storage disease symptoms in pediatric patients depend on its type. These tests may include: Biopsy of the affected organs Blood tests and urine tests MRI scan — a test that uses magnetic waves to make pictures of the inside of the body Glycogen Storage Disease Treatment Glycogen storage disease treatment will depend on the type of disease and the symptoms.
The goal of treatment is to maintain normal blood glucose levels. This may be done with: A nasogastric infusion of glucose in infants and children under age two Dietary changes, including: In children over age two, frequent small carbohydrate feedings are given throughout the day.
This may include uncooked cornstarch. Uncooked cornstarch provides a steady slow-release form of glucose. Elimination of foods that are high in fructose or lactose type I only Allopurinol Aloprim, Zyloprim may be prescribed to reduce uric acid levels in the blood.
This is done to prevent gout and kidney stones. Type IV is sometimes treated with liver transplantation. This is done by: Regulating or limiting strenuous exercise to avoid fatigue symptoms Improving exercise tolerance by oral intake of glucose or fructose fructose must be avoided in people with type I , or an injection of glucagon Eating a high protein diet There is no way to prevent glycogen storage diseases.
Find a Doctor. Contact Us. Pay My Bill. Search by: Last Name Doctor Last Name Practice. Gender Male Female. Language Language Afrikaan Arabic Bengali Bosnian Bulgarian Burmese Cantonese Catalan Chinese Chinese Mandarin Creole Croatian Czech Dutch Farsi Filipino French Gaelic German Greek Gujarati Hebrew Hindi Hungarian Ibo Indian Italian Japanese Kannada Kashmiri Kikuyu Korean Latin Lebanese Lithuanian Malaysian Marathi Persian Polish Portuguese Punjabi Romanian Russian Sanskrit Serbian Sign Language Sindhi Sinhalese Spanish Sri-Lankan Swahili Swedish Tagalog Taiwanese Tamil Telugu Thai Turkish Ukrainian Urdu Vietnamese Yiddish Yoruba.
Official websites use. gov A. gov website Elegant to an official government Myscle in the United Glycogeen. Muscle pain in glycogen storage disease website. Share sensitive information only on official, secure websites. Glycogen storage disease type V also known as GSDV or McArdle disease is an inherited disorder caused by an inability to break down a complex sugar called glycogen in muscle cells.
Die sehr ausgezeichnete Idee
Bemerkenswert, die sehr wertvolle Antwort